RESUMEN
BACKGROUND: Due to recurrent shortages of aminophylline, intravenous caffeine has emerged as a commonly used, safe and reliable method to treat adverse effects of vasodilator stress agents. We sought to evaluate the safety and effectiveness of buccal caffeine strips which are rapidly absorbed, inexpensive, readily available, and simplify caffeine administration. METHODS: Consecutive patients undergoing regadenoson stress SPECT MPI were assessed for the occurrence of symptoms during testing over an 11-week period at a single metropolitan hospital. Adverse symptoms, including their severity and duration, were recorded at the time of testing. Patient satisfaction was rated on a scale of 1 to 5 (5 being the most satisfied). Patients received reversal with caffeine if symptoms were felt to be significant enough by the patient and physician performing the test. The treatment received alternated week to week between IV caffeine (60 mg) or 100 mg buccal caffeine strips. Caffeine was given at least 3 minutes after tracer injection. A rescue dose of IV caffeine was offered 10 minutes later if indicated. RESULTS: Of the 122 patients enrolled in the study, 70 (57%) were included during buccal caffeine weeks and 52 (43%) during IV caffeine weeks, and only 28 (24%) received reversal with a caffeine agent. Seven (6%) received IV caffeine and 21 (17%) received buccal caffeine. There was no significant difference in symptom duration between IV and buccal caffeine after treatment (152.8 vs 163.4 seconds, P = 0.87). There was no significant difference in initial and final symptom severity between groups. Only 2 patients in the buccal group required rescue IV caffeine for ongoing symptoms and emesis. None of the IV group required a rescue dose. There was no significant difference in patient satisfaction between the groups (2.8 vs 3.2, P = 0.38). CONCLUSION: Buccal caffeine strips are a safe, well tolerated, and effective initial strategy to reverse adverse effects of vasodilator stress in the minority of patients who request it. Buccal caffeine alone or with IV rescue caffeine was highly effective in reversing adverse effects and was free of major adverse clinical events.
Asunto(s)
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Imagen de Perfusión Miocárdica , Humanos , Vasodilatadores/efectos adversos , Cafeína , Aminofilina , Tomografía Computarizada de Emisión de Fotón Único/métodos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/etiología , Imagen de Perfusión Miocárdica/métodos , Prueba de Esfuerzo/métodosRESUMEN
Pharmacologic reversal of serious or intolerable side effects (SISEs) from vasodilator stress is an important safety and comfort measure for patients experiencing such effects. While typically performed using intravenous aminophylline, recurrent shortages of this agent have led to a greater need to limit its use and consider alternative agents. This information statement provides background and recommendations addressing indications for vasodilator reversal, timing of a reversal agent, incidence of observed SISE with vasodilator stress, clinical and logistical considerations for aminophylline-based reversal, and alternative non-aminophylline based reversal protocols.
Asunto(s)
Aminofilina/uso terapéutico , Cardiotónicos/uso terapéutico , Vasodilatadores/efectos adversos , Aminofilina/provisión & distribución , Cardiotónicos/provisión & distribución , Prueba de Esfuerzo , Humanos , Imagen de Perfusión Miocárdica , Tomografía Computarizada de Emisión de Fotón ÚnicoRESUMEN
Pharmacologic reversal of serious or intolerable side effects (SISE) from vasodilator stress is an important safety and comfort measure for patients experiencing such effects. While typically performed using intravenous aminophylline, recurrent shortages of this agent have led to a greater need to limit its use and consider alternative agents. This information statement provides background and recommendations addressing indications for vasodilator reversal, timing of a reversal agent, incidence of observed SISE with vasodilator stress, clinical and logistical considerations for aminophylline-based reversal, and alternative non-aminophylline based reversal protocols.
Asunto(s)
Aminofilina/administración & dosificación , Aminofilina/provisión & distribución , Antídotos/administración & dosificación , Antídotos/provisión & distribución , Circulación Coronaria/efectos de los fármacos , Imagen de Perfusión Miocárdica/efectos adversos , Vasodilatación/efectos de los fármacos , Vasodilatadores/efectos adversos , Esquema de Medicación , Humanos , Imagen por Resonancia Magnética , Imagen de Perfusión Miocárdica/métodos , Tomografía de Emisión de Positrones , Factores de Riesgo , Factores de Tiempo , Tomografía Computarizada de Emisión de Fotón Único , Resultado del Tratamiento , Vasodilatadores/administración & dosificaciónRESUMEN
The above position statement originally published containing errors in the author metadata; specifically, the Expert Content Reviewers-Andrew Einstein, Raymond Russell and James R. Corbett-were tagged as full authors of the paper. The article metadata has now been corrected to remove Drs. Einstein, Russell and Corbett from the author line, and the PubMed record has been updated accordingly.
RESUMEN
BACKGROUND: Aminophylline shortages led us to compare intravenous (IV) aminophylline with IV and oral (PO) caffeine during routine pharmacologic stress testing with SPECT MPI. METHODS: We measured presence, duration, and reversal of adverse symptoms and cardiac events following regadenoson administration in consecutive patients randomized to IV aminophylline (100 mg administered over 30-60 seconds), IV caffeine citrate (60 mg infused over 3-5 minutes), or PO caffeine as coffee or diet cola. RESULTS: Of 241 patients, 152 (63%) received regadenoson reversal intervention. Complete (CR), predominant (PRE), or partial (PR) reversal was observed in 99%. CR by IV aminophylline (87%), IV caffeine (87%), and PO caffeine (78%) were similar (P = NS). Time to CR (162 ± 12.6 seconds, mean ± SD) was similar in treatment arms. PO caffeine was inferior to IV aminophylline for CR + PRE. CONCLUSIONS: IV aminophylline and IV caffeine provide rapid, safe reversal of regadenoson-induced adverse effects during SPECT MPI. Oral caffeine appeared similarly effective for CR but not for the combined CR + PRE. Our results suggest PO caffeine may be an effective initial strategy for reversal of regadenoson, but IV aminophylline or IV caffeine should be available to optimize symptom reversal as needed.
Asunto(s)
Aminofilina/administración & dosificación , Cafeína/administración & dosificación , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/mortalidad , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Imagen de Perfusión Miocárdica/estadística & datos numéricos , Purinas/administración & dosificación , Pirazoles/administración & dosificación , Tomografía Computarizada de Emisión de Fotón Único/estadística & datos numéricos , Administración Oral , Anciano , Cardiotónicos/administración & dosificación , Causalidad , Interacciones Farmacológicas , Prueba de Esfuerzo/efectos de los fármacos , Femenino , Humanos , Incidencia , Inyecciones Intravenosas , Masculino , Persona de Mediana Edad , Imagen de Perfusión Miocárdica/mortalidad , New York/epidemiología , Tasa de Supervivencia , Tomografía Computarizada de Emisión de Fotón Único/mortalidad , Resultado del Tratamiento , Vasodilatadores/administración & dosificaciónRESUMEN
PURPOSE OF REVIEW: Cardiotoxicity is an important complication of cancer therapy. With a significant improvement in the overall survival and prognosis of patients undergoing cancer therapy, cardiovascular toxicity of cancer therapy has become an important public health issue. Several well-established as well as newer anticancer therapies such as anthracyclines, trastuzumab, and other HER2 receptor blockers, antimetabolites, alkylating agents, tyrosine kinase inhibitors, angiogenesis inhibitors, checkpoint inhibitors, and thoracic irradiation are associated with significant cardiotoxicity. RECENT FINDINGS: Cardiovascular imaging employing radionuclide imaging, echocardiography, and magnetic resonance imaging is helpful in early detection of the cardiotoxicity and prevention of overt heart failure. These techniques also provide important tools for understanding the mechanism of cardiotoxicity of these modalities, which would help develop strategies for the prevention of cardiac morbidity and mortality related to the use of these agents. An understanding of the mechanism of the cardiotoxicity of cancer therapies can help prevent and treat their adverse cardiovascular consequences. Clinical implementation of algorithms based upon cardiac imaging and several non-imaging biomarkers can prevent cardiac morbidity and mortality associated with the use of cardiotoxic cancer therapies.
Asunto(s)
Antraciclinas/efectos adversos , Antineoplásicos/efectos adversos , Técnicas de Imagen Cardíaca/efectos adversos , Cardiotoxicidad/prevención & control , Insuficiencia Cardíaca/prevención & control , Neoplasias/tratamiento farmacológico , Función Ventricular Izquierda/efectos de los fármacos , Técnicas de Imagen Cardíaca/tendencias , Guías como Asunto , Insuficiencia Cardíaca/inducido químicamente , Humanos , PronósticoAsunto(s)
Hipoxia/diagnóstico por imagen , Tomografía Computarizada por Tomografía de Emisión de Positrones/normas , Sarcoidosis/complicaciones , Fluorodesoxiglucosa F18/administración & dosificación , Fluorodesoxiglucosa F18/uso terapéutico , Corazón/diagnóstico por imagen , Corazón/fisiopatología , Humanos , Hipoxia/etiología , Tomografía Computarizada por Tomografía de Emisión de Positrones/métodos , Tomografía Computarizada por Tomografía de Emisión de Positrones/estadística & datos numéricos , Radiofármacos/administración & dosificación , Radiofármacos/uso terapéutico , Sarcoidosis/diagnóstico por imagenRESUMEN
With the increasing number of individuals living with a current or prior diagnosis of cancer, it is important for the cardiovascular specialist to recognize the various complications of cancer and its therapy on the cardiovascular system. This is true not only for established cancer therapies, such as anthracyclines, that have well established cardiovascular toxicities, but also for the new targeted therapies that can have "off target" effects in the heart and vessels. The purpose of this informational statement is to provide cardiologists, cardiac imaging specialists, cardio-oncologists, and oncologists an understanding of how multimodality imaging may be used in the diagnosis and management of the cardiovascular complications of cancer therapy. In addition, this document is meant to provide useful general information concerning the cardiovascular complications of cancer and cancer therapy as well as established recommendations for the monitoring of specific cardiotoxic therapies.
Asunto(s)
Antineoplásicos/efectos adversos , Técnicas de Imagen Cardíaca/métodos , Cardiopatías/diagnóstico por imagen , Cardiopatías/etiología , Imagen Multimodal/métodos , Traumatismos por Radiación/diagnóstico por imagen , Radioterapia/efectos adversos , Medicina Basada en la Evidencia , Humanos , Traumatismos por Radiación/etiología , Tomografía Computarizada de Emisión/métodosAsunto(s)
Fluorodesoxiglucosa F18 , Sarcoidosis , Corazón , Humanos , Miocardio , Tomografía de Emisión de PositronesRESUMEN
BACKGROUND: Obesity is a common source of artifact on conventional SPECT myocardial perfusion imaging (MPI). We evaluated image quality and diagnostic performance of high-efficiency (HE) cadmium-zinc-telluride parallel-hole SPECT MPI for coronary artery disease (CAD) in obese patients. METHODS AND RESULTS: 118 consecutive obese patients at three centers (BMI 43.6 ± 8.9 kg·m(-2), range 35-79.7 kg·m(-2)) had upright/supine HE-SPECT and invasive coronary angiography > 6 months (n = 67) or low likelihood of CAD (n = 51). Stress quantitative total perfusion deficit (TPD) for upright (U-TPD), supine (S-TPD), and combined acquisitions (C-TPD) was assessed. Image quality (IQ; 5 = excellent; < 3 nondiagnostic) was compared among BMI 35-39.9 (n = 58), 40-44.9 (n = 24) and ≥45 (n = 36) groups. ROC curve area for CAD detection (≥50% stenosis) for U-TPD, S-TPD, and C-TPD were 0.80, 0.80, and 0.87, respectively. Sensitivity/specificity was 82%/57% for U-TPD, 74%/71% for S-TPD, and 80%/82% for C-TPD. C-TPD had highest specificity (P = .02). C-TPD normalcy rate was higher than U-TPD (88% vs 75%, P = .02). Mean IQ was similar among BMI 35-39.9, 40-44.9 and ≥45 groups [4.6 vs 4.4 vs 4.5, respectively (P = .6)]. No patient had a nondiagnostic stress scan. CONCLUSIONS: In obese patients, HE-SPECT MPI with dedicated parallel-hole collimation demonstrated high image quality, normalcy rate, and diagnostic accuracy for CAD by quantitative analysis of combined upright/supine acquisitions.
Asunto(s)
Artefactos , Enfermedad de la Arteria Coronaria/complicaciones , Enfermedad de la Arteria Coronaria/diagnóstico por imagen , Aumento de la Imagen/métodos , Tomografía Computarizada de Emisión de Fotón Único/instrumentación , Compuestos de Cadmio , California , Diseño de Equipo , Análisis de Falla de Equipo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Imagen de Perfusión Miocárdica/métodos , Obesidad/complicaciones , Reproducibilidad de los Resultados , Compuestos de Selenio , Sensibilidad y Especificidad , Transductores , Compuestos de ZincRESUMEN
State of the art of cardiac SPECT imaging continues to advance. Contemporary clinical applications of cardiac SPECT are reviewed and illustrated. Beyond traditional stress and rest myocardial perfusion imaging, the role of digital SPECT technology, ultra low dose imaging with efficient stress first / stress only if normal imaging, deep learning algorithms relative to coronary angiography and SPECT CT, sourceless emission attenuation correction, myocardial blood flow and blood flow reserve to assess ischemic jeopardy, culprit ischemic territories, and cardiac allograft vasculopathy, advanced methods of SPECT detection of amyloid cardiomyopathy, resting MPI to define pre-operative regional scar prior to operative ablation, parametric radionuclide ventriculography to quantify dyssynchrony and benefit of biventricular pacing, assessment of treatment response of RV and LV function in patients with pulmonary hypertension, dual isotope MIBG imaging to assess cardiac risk, and the value proposition of real world effectiveness of SPECT cardiac imaging are illustrated.